bit.bio
bit.bio
Actively hiring
Synthetic Biology
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Series C · Jan 2026 · 8 mo ago
Team
11-50
employees, estimated range
Backers
3
ARCH Venture Partners, BlueYard Capital
The money's age
Fresh money
8 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 27, 2025
Launched bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types · PRNewswire
2016
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series C | Jan 2026 | $50M | M&G lead | Pulse 2.0 |
Registers and programsofficial lists and records that name the company
| Legal entity | Bit Bio Limited | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners 
BlueYard Capital 
Foresite Capital Similar startupsby what they do, their industry and backers
MEASURING, PREDICTING, ANDENGINEERING PROTEIN INTERACTIONS at Scale. A-Alpha Bio harnesses synthetic biology and machine learning to…
EditCo provides CRISPR gene editing services, CRISPR products & genome engineering solutions for disease models, drug discovery and cell…
Logomix is a Japan-based synthetic biology company that develops genome engineering technologies for human cells. Its Geno-Writing platform…
Asimov builds tools to program living cells. We're integrating mammalian synthetic biology with computer-aided design to advance…
Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology…
By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a…
News
bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform
M&G Investments has led a $50 million Series C funding round for bit.bio, a Cambridge-based biotechnology company developing human cell programming technology to improve the speed and predictability of drug discovery and safety testing.
Read more
Report
bit.bio Publishes 2025 Sustainability Report
bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming its commitment to measurable progress across ethics, sustainability, and operational impact.
Read more
Report
bit.bio Publishes 2025 Sustainability Report
/PRNewswire/ -- bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report,...
Read more
Report
bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types
Researchers can easily track and isolate bit.bio
Read more
Report
bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox Cell Programming Technology
bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational Europe...
Read more
Report
Pro access
Upgrade to see all 7 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United Kingdom
Regional office
Cambridge
The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, CB22 3FH
Oxford
United Kingdom
Regional office
Oxford
Financials
Total raised
$50M
Latest round
Series C
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series C | 2026 | $50M | Details |